1. Home
  2. TLIH vs AKTX Comparison

TLIH vs AKTX Comparison

Compare TLIH & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TLIH

Ten-League International Holdings Limited Ordinary Shares

N/A

Current Price

$4.60

Market Cap

12.9M

Sector

N/A

ML Signal

N/A

Logo Akari Therapeutics plc ADS

AKTX

Akari Therapeutics plc ADS

HOLD

Current Price

$10.02

Market Cap

17.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TLIH
AKTX
Founded
1998
N/A
Country
Singapore
United States
Employees
70
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.9M
17.2M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
TLIH
AKTX
Price
$4.60
$10.02
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$33.50
AVG Volume (30 Days)
13.4K
179.4K
Earning Date
05-01-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$3.34
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.22
$0.12
52 Week High
$7.00
$29.32

Technical Indicators

Market Signals
Indicator
TLIH
AKTX
Relative Strength Index (RSI) 67.05 45.96
Support Level $0.32 $0.32
Resistance Level N/A $29.32
Average True Range (ATR) 0.34 1.49
MACD -0.05 -0.80
Stochastic Oscillator 97.09 17.06

Price Performance

Historical Comparison
TLIH
AKTX

About TLIH Ten-League International Holdings Limited Ordinary Shares

Ten-League International Holdings Ltd is a Singapore-based provider of turnkey project solutions. Its business consists of sales of heavy equipment and parts, heavy equipment rental, and provision of engineering consultancy services to port, construction, civil engineering, and underground foundation industries. It currently conducts its operations through its wholly-owned subsidiaries. The equipment it provides is organized into four categories based on their functions and application scenarios, namely, foundation equipment, hoist equipment, excavation equipment, and port machinery. The company operates in Singapore and Other international countries.

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.

Share on Social Networks: